Vogt A - Search Results

1

The antisignaling agent SC-alpha alpha delta 9, 4-(benzyl-(2-[(2,5-diphenyloxazole-4-carbonyl)amino]ethyl)carbamoyl)- 2-decanoylaminobutyric acid, is a structurally unique phospholipid analogue with phospholipase C inhibitory activity.

Vogt A, Pestell KE, Day BW, Lazo JS, Wipf P. Vogt A, et al. Mol Cancer Ther. 2002 Sep;1(11):885-92. Mol Cancer Ther. 2002. PMID: 12481409

2

Disruption of insulin-like growth factor-1 signaling and down-regulation of cdc2 by SC-alphaalphadelta9, a novel small molecule antisignaling agent identified in a targeted array library.

Vogt A, Rice RL, Settineri CE, Yokokawa F, Yokokawa S, Wipf P, Lazo JS. Vogt A, et al. J Pharmacol Exp Ther. 1998 Nov;287(2):806-13. J Pharmacol Exp Ther. 1998. PMID: 9808713

3

In vivo antitumor activity and induction of insulin-like growth factor-1-resistant apoptosis by SC-alphaalphadelta9.

Vogt A, Wang AS, Johnson CS, Fabisiak JP, Wipf P, Lazo JS. Vogt A, et al. J Pharmacol Exp Ther. 2000 Feb;292(2):530-7. J Pharmacol Exp Ther. 2000. PMID: 10640289

4

Antitumor imidazolyl disulfide IV-2 causes irreversible G(2)/M cell cycle arrest without hyperphosphorylation of cyclin-dependent kinase Cdk1.

Vogt A, Tamura K, Watson S, Lazo JS. Vogt A, et al. J Pharmacol Exp Ther. 2000 Sep;294(3):1070-5. J Pharmacol Exp Ther. 2000. PMID: 10945861

5

Antimitotic actions of a novel analog of the fungal metabolite palmarumycin CP1.

Lazo JS, Tamura K, Vogt A, Jung JK, Rodriguez S, Balachandran R, Day BW, Wipf P. Lazo JS, et al. Among authors: vogt a. J Pharmacol Exp Ther. 2001 Feb;296(2):364-71. J Pharmacol Exp Ther. 2001. PMID: 11160619

6

Spatial analysis of key signaling proteins by high-content solid-phase cytometry in Hep3B cells treated with an inhibitor of Cdc25 dual-specificity phosphatases.

Vogt A, Adachi T, Ducruet AP, Chesebrough J, Nemoto K, Carr BI, Lazo JS. Vogt A, et al. J Biol Chem. 2001 Jun 8;276(23):20544-50. doi: 10.1074/jbc.M100078200. Epub 2001 Mar 26. J Biol Chem. 2001. PMID: 11274178 Free article.

7

Discovery and biological evaluation of a new family of potent inhibitors of the dual specificity protein phosphatase Cdc25.

Lazo JS, Aslan DC, Southwick EC, Cooley KA, Ducruet AP, Joo B, Vogt A, Wipf P. Lazo JS, et al. Among authors: vogt a. J Med Chem. 2001 Nov 22;44(24):4042-9. doi: 10.1021/jm0102046. J Med Chem. 2001. PMID: 11708908

8

Cell-active dual specificity phosphatase inhibitors identified by high-content screening.

Vogt A, Cooley KA, Brisson M, Tarpley MG, Wipf P, Lazo JS. Vogt A, et al. Chem Biol. 2003 Aug;10(8):733-42. doi: 10.1016/s1074-5521(03)00170-4. Chem Biol. 2003. PMID: 12954332

9

Activation of the Raf-1/MEK/Erk kinase pathway by a novel Cdc25 inhibitor in human prostate cancer cells.

Nemoto K, Vogt A, Oguri T, Lazo JS. Nemoto K, et al. Among authors: vogt a. Prostate. 2004 Jan 1;58(1):95-102. doi: 10.1002/pros.10292. Prostate. 2004. PMID: 14673957

10

A scalable high-content cytotoxicity assay insensitive to changes in mitochondrial metabolic activity.

Vogt A, Kalb EN, Lazo JS. Vogt A, et al. Oncol Res. 2004;14(6):305-14. doi: 10.3727/096504003773994842. Oncol Res. 2004. PMID: 15206493

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,053 results

Search Page

Filters